USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
APAC to see a reduction in imported surgical robotics
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
Exceeding the target of 1.50 lakh Ayushman Bharat - Health & Wellness Centres (AB-HWC) by 31 December, 2022, more than 1.54 lakh Sub Health Centres and Primary Health Centres have been transformed as AB-HWCs
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.
Subscribe To Our Newsletter & Stay Updated